Part two of our look at Matt McCall's Chinese biotech stock pitch
16 Comments Read MoreWe use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More InfoWe use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
Viva Biotech certainly makes a good fit. It is the 3rd largest holding in the Open Door China Healthcare Fund (after 3...
Also Amgen has taken a stake in Beigene at a premium which caused the latest sharp price increase at the end of October....